Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00117091
Status:
COMPLETED
Last Update Posted:
2007-12-24
First Post:
2005-06-30
Brief Title:
Anakinra Kineret in Combination With Disease Modifying Anti-Rheumatic Drugs DMARDS in Subjects With Active Rheumatoid Arthritis RA
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-Label Multicentre Study of Anakinra Kineret in Combination With DMARDS in Subjects With Active Rheumatoid Arthritis RA
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the percentage of subjects in Australian clinical practice continuing treatment with Anakinra Kineret at the end of study week 48 in subjects with active RA The continued use of Kineret will be based on pre-defined response assessment criteria for subjects with active RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None